Office Number: 203-230-8596
CaroGen Corporation is an emerging biopharmaceutical company employing a virus-like vesicle (VLV) vaccine platform technology developed at Yale University School of Medicine and exclusively licensed for the development and commercialization of vaccines worldwide.
Our vision is to create new, potentially transformative and first-in-class nanoparticle therapeutic vaccines designed to engage the body’s immune system to both recognize and fight off infectious diseases and cancer. The company is developing a portfolio of vaccine candidates with a lead vaccine program in chronic hepatitis B viral infection – a pathogen of global concern and a leading cause of liver disease and cancer.
The hepatitis B program has completed initial proof-of-concept testing in animals and is undergoing optimization for selection of a clinical candidate. We are engaged in discussions and research with academic partners on additional targets and models to assess the efficacy of VLV vaccines against these targets to expand the product pipeline.
CaroGen Wins Entrepreneur Innovation Award from CTNext
Hamden CT – April 3, 2014 – CaroGen was awarded a $10,000 grant by CTNext, a component of Connecticut’s innovation ecosystem to support the success of companies and entrepreneurs, to further support development of its therapeutic vaccine for chronic Hepatitis B (CHB) viral infection.
CaroGen Corporation Awarded “Most Promising Life Science Product”
Hamden CT - November 8, 2013 - A panel of industry experts, angel and venture capital investors awarded CaroGen Corporation the Most Promising Life Sciences Product at the 2013 Connecticut Innovation Summit.
CaroGen's Sponsored Research Agreement (SRA) with Yale University
Hamden CT – August 20, 2013 – A corporate research agreement involving CaroGen Corporation’s novel recombinant virus-like vesicle (VLV) technology was signed between the Company and Yale University. CaroGen is a biotechnology firm pioneering breakthrough technology for the development of novel vaccines.